An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Breast Cancer Content
Targeting the PI3K/AKT pathway in HR+ HER2- advanced breast cancer
Watch leading experts discuss new and emerging agents targeting the PI3K/AKT pathway in HR+ HER2- breast cancer, including how to manage key side effects.
- Recall the rationale for targeting the PI3K/AKT pathway in HR+ HER2- breast cancer and approved/investigational agents that target this pathway
- Review the safety data for approved and emerging drugs targeting the PI3K/AKT pathway in HR+ HER2- breast cancer
- Discuss the management of key side effects associated with drugs targeting the PI3K/AKT pathway
Antibody-drug conjugates for patients with solid tumours: Practical analysis of the latest data from ESMO 2020
Watch this two-part activity discussing the latest developments in antibody-drug conjugates for solid tumours. Filmed following presentations at ESMO 2020. Part 1: Watch internationally renowned expert Mikel Ross review key data from the congress Watch Now Part 2: Choose from leading experts who discuss what the latest data mean for global and regional practice Select An Interview
- Recognize the antibody drug conjugates (ADCs) that are available for the treatment of solid tumours
- Summarize how emerging and evolving ADCs may improve outcomes for patients with solid tumours
- Discuss practical strategies for the management of adverse events associated with approved ADCs for solid tumours
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
Aditya Bardia, ESMO 2020 – Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: the ASCENT Trial
touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s […]
Stephen Johnston, ESMO 2020 – The MonarchE trial and Abemaciclib in High-risk Early Breast Cancer
Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 […]
Managing brain metastases in advanced HER2-positive breast cancer
Get up to date on the data for emerging treatment options for patients with HER2-positive breast cancer and brain metastases and how they may influence clinical practice by watching these short interviews with breast cancer experts.
- Recognize the unmet needs of patients with advanced HER2-positive breast cancer and brain metastases
- Review the clinical data for emerging treatment options for patients with advanced HER2-positive breast cancer and brain metastases
- Determine how novel HER2-targeted therapies may change the future management of patients with HER2-positive breast cancer and brain metastases
Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer
Oncology & Hematology Review (US). 2020;16(1):23-9 DOI: https://doi.org/10.17925/OHR.2020.16.1.23
Since the approval of palbociclib in 2015,1 cyclin dependent kinase (CDK) 4/6 inhibitors have been a heavily-researched and discussed class of medication for the management of metastatic, hormone receptor positive (HR+), human epidermal growth factor receptor 2-unamplified (HER2-) breast cancer. Because their approval and rise to prominence was based on benefit seen in progression-free survival […]
Emerging HER-targeted antibody-drug conjugates for advanced breast cancer: What are we discovering?
Watch Dr King, an internationally renowned oncology expert, discuss the latest data on human epidermal growth factor receptor-targeted antibody-drug conjugates for the treatment of breast cancer.
- Describe how the structure and mechanism of action of antibody-drug conjugates may address current unmet treatment needs in patients with advanced breast cancer
- Evaluate clinical data for emerging anti-HER2 antibody-drug conjugates used to treat patients with HER2-positive advanced breast cancer
- Discuss how clinical practice may change with the emergence of novel HER-targeted antibody-drug conjugates for patients with advanced breast cancer
From publication to practice: How trial data translate to clinical use of CDK4/6 Inhibitors in patients with HR+/HER2- advanced breast cancer
Watch leading international experts in breast cancer translate outcomes from key clinical trials investigating CDK4/6 inhibitors in HR+/HER2- advanced breast cancer into daily practice
- Identify patients with HR+/HER2- advanced breast cancer suitable for treatment with a CDK4/6 inhibitor
- Understand the key differences between the CDK4/6 inhibitors and how these might influence drug choice for individual patients
- Apply knowledge of the CDK4/6 inhibitor’s dosing, safety profile and monitoring requirements to optimize patient management
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!